Introduction of Committee Chair
Conflict
of Interest Statement
Opening Remarks Daniel Shames, M.D.
Director,
Division of Reproductive and Urologic Drug Products (DRUDP)
FDA
______________________________________________________________________________
Issues relevant to the
conduct of clinical trials and outcome measures for consideration of approval
of drug products for the indications of induction of ovulation and pregnancy in
anovulatory, infertile women and development of multiple follicles, and
pregnancy in ovulatory women participating in assisted reproductive technology
(ART) programs.
Reproductive Technology - Director,
Reproductive Medicine and
Background & State of
Practice Infertility
Director
______________________________________________________________________________
Medical
Officer Team Leader
Division of Reproductive
and Urologic
Drug Products (DRUDP)